Gsk3-mediated maf phosphorylation in multiple myeloma as a potential therapeutic target

Blood Cancer Journal

Volumn 4, Issue 1, 2014, Pages

  Herath, N I ^a,b,c   Rocques, N ^a,b,c   Garancher, A ^a,b,c   Eychene A ^a,b,c   Pouponnot, C ^a,b,c  

^a INSTITUT CURIE   (France)

^b Centre National de la Recherche Scientifique   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

C MAF; GSK3; Lithium; MAFA; MAFB; Multiple myeloma

Indexed keywords

EID: 85047339757     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2013.67     Document Type: Article

References (40)

1. Chng WJ, Glebov O, Bergsagel PL, Kuehl WM. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol 2007; 20: 571–596.
2. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007; 7: 585–598.
3. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002; 2: 175–187.
4. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012; 12: 335–348.
5. Chesi M, Bergsagel PL. Many multiple myelomas: making more of the molecular mayhem. Hematol Am Soc Hematol Educ Program 2011; 2011: 344–353.
6. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S et al. The molecular classification of multiple myeloma. Blood 2006; 108: 2020–2028.
7. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23: 2210–2221.
8. Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San Miguel JF. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 2013; 121: 884–892.
9. Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011; 117: 4696–4700.
10. Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011; 8: 479–491.
11. Rajkumar SV. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013; 88: 225–235.
12. Avet-Loiseau H, Malard F, Campion L, Magrangeas F, Sebban C, Lioure B et al. Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood 2011; 117: 2009–2011.
13. Eychene A, Rocques N, Pouponnot C. A new MAFia in cancer. Nat Rev Cancer 2008; 8: 683–693.
14. Pouponnot C, Sii-Felice K, Hmitou I, Rocques N, Lecoin L, Druillennec S et al. Cell context reveals a dual role for Maf in oncogenesis. Oncogene 2006; 25: 1299–1310.
15. Kataoka K, Shioda S, Yoshitomo-Nakagawa K, Handa H, Nishizawa M. Maf and Jun nuclear oncoproteins share downstream target genes for inducing cell transformation. J Biol Chem 2001; 276: 36849–36856.
16. Nishizawa M, Kataoka K, Vogt PK. MafA has strong cell transforming ability but is a weak transactivator. Oncogene 2003; 22: 7882–7890.
17. Rocques N, Abou Zeid N, Sii-Felice K, Lecoin L, Felder-Schmittbuhl MP, Eychene A et al. GSK-3-mediated phosphorylation enhances Maf-transforming activity. Mol Cell 2007; 28: 584–597.
18. Han SI, Aramata S, Yasuda K, Kataoka K. MafA stability in pancreatic beta cells is regulated by glucose and is dependent on its constitutive phosphorylation at multiple sites by glycogen synthase kinase 3. Mol Cell Biol 2007; 27: 6593–6605.
19. Chesi M, Bergsagel PL, Shonukan OO, Martelli ML, Brents LA, Chen T et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 1998; 91: 4457–4463.
20. Hanamura I, Iida S, Akano Y, Hayami Y, Kato M, Miura K et al. Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations. Jpn J Cancer Res 2001; 92: 638–644.
21. Boersma-Vreugdenhil GR, Kuipers J, Van Stralen E, Peeters T, Michaux L, Hagemeijer A et al. The recurrent translocation t(14;20)(q32;q12) in multiple myeloma results in aberrant expression of MAFB: a molecular and genetic analysis of the chromosomal breakpoint. Br J Haematol 2004; 126: 355–363.
22. Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004; 5: 191–199.
23. Annunziata CM, Hernandez L, Davis RE, Zingone A, Lamy L, Lam LT et al. A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood 2011; 117: 2396–2404.
24. Suzuki A, Iida S, Kato-Uranishi M, Tajima E, Zhan F, Hanamura I et al. ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma. Oncogene 2005; 24: 6936–6944.
25. Morito N, Yoh K, Fujioka Y, Nakano T, Shimohata H, Hashimoto Y et al. Overexpression of c-Maf contributes to T-cell lymphoma in both mice and human. Cancer Res 2006; 66: 812–819.
26. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009; 137: 873–886.
27. van Stralen E, van de Wetering M, Agnelli L, Neri A, Clevers HC, Bast BJ. Identification of primary MAFB target genes in multiple myeloma. Exp Hematol 2009; 37: 78–86.
28. Morito N, Yoh K, Maeda A, Nakano T, Fujita A, Kusakabe M et al. A novel transgenic mouse model of the human multiple myeloma chromosomal translocation t(14;16)(q32;q23). Cancer Res 2011; 71: 339–348.
29. Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 2012; 122: 3456–3463.
30. Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol 2012; 9: 135–143.
31. Benkhelifa S, Provot S, Lecoq O, Pouponnot C, Calothy G, Felder-Schmittbuhl MP. mafA, a novel member of the maf proto-oncogene family, displays developmental regulation and mitogenic capacity in avian neuroretina cells. Oncogene 1998; 17: 247–254.
32. Patel S, Woodgett J. Glycogen synthase kinase-3 and cancer: good cop, bad cop? Cancer Cell 2008; 14: 351–353.
33. Billadeau DD. Primers on molecular pathways. The glycogen synthase kinase-3beta. Pancreatology 2007; 7: 398–402.
34. Ougolkov AV, Billadeau DD. Targeting GSK-3: a promising approach for cancer therapy? Future Oncol 2006; 2: 91–100.
35. Wang Z, Smith KS, Murphy M, Piloto O, Somervaille TC, Cleary ML. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 2008; 455: 1205–1209.
36. Wang Z, Iwasaki M, Ficara F, Lin C, Matheny C, Wong SH et al. GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. Cancer Cell 2010; 17: 597–608.
37. Busino L, Millman SE, Scotto L, Kyratsous CA, Basrur V, O’Connor O et al. Fbxw7alpha-and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nat Cell Biol 2012; 14: 375–385.
38. Geng F, Wenzel S, Tansey WP. Ubiquitin and proteasomes in transcription. Annu Rev Biochem 2012; 81: 177–201.
39. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003; 116: 1175–1186.
40. Li X, Jope RS. Is glycogen synthase kinase-3 a central modulator in mood regulation? Neuropsychopharmacology 2010; 35: 2143–2154.